By Staff Reporter, GenomeWeb, July 7, 2022
NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.
Related Reference: Science Translational Medicine; Jul 6 2022 Vol 14, Issue 652 DOI: 10.1126/scitranslmed.abn192
SOURCES: https://www.genomeweb.com/sequencing/breast-ovarian-cancer-study-finds-ties-between-types-brca-alterations-treatment-response?adobe_mc=MCMID%3D57978272016016530324056426844147474339%7CMCORGID%3D138FFF2554E6E7220A4C98C6%2540AdobeOrg%7CTS%3D1657224852&CSAuthResp=1%3A%3A2208906%3A273%3A24%3Asuccess%3AC802D6A89ABCAE21D5A3F9C2D546125F#.Ysc-muzMJhE; https://www.science.org/doi/10.1126/scitranslmed.abn1926
Categories: DPC News